Creo Medical Group PLC (LON:CREO - Get Free Report)'s stock price shot up 17.8% during trading on Wednesday . The company traded as high as GBX 16.20 ($0.22) and last traded at GBX 16.20 ($0.22). 8,278,319 shares traded hands during trading, an increase of 510% from the average session volume of 1,356,147 shares. The stock had previously closed at GBX 13.75 ($0.19).
Creo Medical Group Price Performance
The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24. The stock has a market capitalization of £62.66 million, a P/E ratio of -2.45 and a beta of 0.86. The stock has a 50-day simple moving average of GBX 11.09 and a 200 day simple moving average of GBX 14.83.
Creo Medical Group (LON:CREO - Get Free Report) last released its earnings results on Monday, May 19th. The company reported GBX (8) (($0.11)) earnings per share (EPS) for the quarter. Creo Medical Group had a negative net margin of 73.93% and a negative return on equity of 41.79%. On average, equities analysts forecast that Creo Medical Group PLC will post -10.0800005 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Kevin Crofton purchased 701,750 shares of the stock in a transaction dated Friday, May 30th. The stock was bought at an average cost of GBX 16 ($0.22) per share, with a total value of £112,280 ($151,117.09). Company insiders own 22.43% of the company's stock.
About Creo Medical Group
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Featured Stories
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
